JP5989250B2 - Ｍｇｌｕｒ５受容体活性のモジュレーターとしてのエチニル誘導体 - Google Patents

Ｍｇｌｕｒ５受容体活性のモジュレーターとしてのエチニル誘導体 Download PDF

Info

Publication number
JP5989250B2
JP5989250B2 JP2015535066A JP2015535066A JP5989250B2 JP 5989250 B2 JP5989250 B2 JP 5989250B2 JP 2015535066 A JP2015535066 A JP 2015535066A JP 2015535066 A JP2015535066 A JP 2015535066A JP 5989250 B2 JP5989250 B2 JP 5989250B2
Authority
JP
Japan
Prior art keywords
compound
formula
chloro
morpholin
phenylethynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015535066A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531392A (ja
JP2015531392A5 (enExample
Inventor
ヤーシュケ，ゲオルク
リンデマン，ローター
リッチ，アントーニオ
リュエル，ダニエル
シュタードラー，ハインツ
フィエイラ，エリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2015531392A publication Critical patent/JP2015531392A/ja
Publication of JP2015531392A5 publication Critical patent/JP2015531392A5/ja
Application granted granted Critical
Publication of JP5989250B2 publication Critical patent/JP5989250B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Epidemiology (AREA)
JP2015535066A 2012-10-18 2013-10-15 Ｍｇｌｕｒ５受容体活性のモジュレーターとしてのエチニル誘導体 Expired - Fee Related JP5989250B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12188940 2012-10-18
EP12188940.6 2012-10-18
PCT/EP2013/071500 WO2014060398A1 (en) 2012-10-18 2013-10-15 Ethynyl derivatives as modulators of mglur5 receptor activity

Publications (3)

Publication Number Publication Date
JP2015531392A JP2015531392A (ja) 2015-11-02
JP2015531392A5 JP2015531392A5 (enExample) 2016-07-28
JP5989250B2 true JP5989250B2 (ja) 2016-09-07

Family

ID=47049067

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015535066A Expired - Fee Related JP5989250B2 (ja) 2012-10-18 2013-10-15 Ｍｇｌｕｒ５受容体活性のモジュレーターとしてのエチニル誘導体

Country Status (26)

Country Link
US (1) US9227959B2 (enExample)
EP (1) EP2909180B1 (enExample)
JP (1) JP5989250B2 (enExample)
KR (1) KR101684816B1 (enExample)
CN (1) CN104718192B (enExample)
AR (1) AR093042A1 (enExample)
AU (1) AU2013333988B2 (enExample)
BR (1) BR112015006454A8 (enExample)
CA (1) CA2882520A1 (enExample)
CL (1) CL2015000891A1 (enExample)
CO (1) CO7200248A2 (enExample)
CR (1) CR20150144A (enExample)
EA (1) EA025667B1 (enExample)
ES (1) ES2599553T3 (enExample)
IL (1) IL237380A (enExample)
MA (1) MA38012B1 (enExample)
MX (1) MX2015004898A (enExample)
MY (1) MY168937A (enExample)
NZ (1) NZ705144A (enExample)
PE (1) PE20150629A1 (enExample)
PH (1) PH12015500398A1 (enExample)
SG (1) SG11201501392TA (enExample)
TW (1) TWI490208B (enExample)
UA (1) UA114529C2 (enExample)
WO (1) WO2014060398A1 (enExample)
ZA (1) ZA201500856B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909178B1 (en) * 2012-10-18 2016-10-05 F. Hoffmann-La Roche AG Ethynyl derivatives as modulators of mglur5 receptor activity
JP6603334B2 (ja) 2015-06-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー エチニル誘導体
WO2017053769A1 (en) * 2015-09-25 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Triazole derivatives as p2y14 receptor antagonists
ES2897050T3 (es) 2017-12-08 2022-02-28 Boehringer Ingelheim Int Derivados de imidazopiridina y el uso de los mismos como medicamento
MA53898B1 (fr) 2018-10-17 2023-03-31 Boehringer Ingelheim Int Dérivés de 4-pyrazin-2-ylméthyl-morpholine et leur utilisation comme médicament
CN112888684B (zh) 2018-10-17 2023-10-10 勃林格殷格翰国际有限公司 4-嘧啶-5-基甲基-吗啉衍生物及其作为药物的用途
WO2020079042A1 (en) 2018-10-17 2020-04-23 Boehringer Ingelheim International Gmbh 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
JP7318015B2 (ja) 2019-06-04 2023-07-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特に抑うつ病性障害の処置のための、ｎｒ２ｂネガティブ調節剤としてのプリン誘導体および医薬としてのその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
CA2689282A1 (en) * 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
WO2013049255A1 (en) * 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors

Also Published As

Publication number Publication date
JP2015531392A (ja) 2015-11-02
AR093042A1 (es) 2015-05-13
HK1207639A1 (zh) 2016-02-05
CN104718192B (zh) 2016-08-31
IL237380A0 (en) 2015-04-30
IL237380A (en) 2017-02-28
MA38012A1 (fr) 2016-05-31
CN104718192A (zh) 2015-06-17
TWI490208B (zh) 2015-07-01
TW201420571A (zh) 2014-06-01
CR20150144A (es) 2015-04-30
EP2909180A1 (en) 2015-08-26
CL2015000891A1 (es) 2015-09-11
EA025667B1 (ru) 2017-01-30
UA114529C2 (uk) 2017-06-26
EP2909180B1 (en) 2016-10-05
EA201590699A1 (ru) 2015-07-30
AU2013333988A1 (en) 2015-02-26
BR112015006454A8 (pt) 2019-08-20
WO2014060398A1 (en) 2014-04-24
CA2882520A1 (en) 2014-04-24
PH12015500398B1 (en) 2015-04-27
BR112015006454A2 (pt) 2017-07-04
KR20150055044A (ko) 2015-05-20
ES2599553T3 (es) 2017-02-02
PH12015500398A1 (en) 2015-04-27
US20150225385A1 (en) 2015-08-13
MA38012B1 (fr) 2016-12-30
KR101684816B1 (ko) 2016-12-20
US9227959B2 (en) 2016-01-05
NZ705144A (en) 2018-09-28
PE20150629A1 (es) 2015-05-11
AU2013333988B2 (en) 2017-03-09
CO7200248A2 (es) 2015-02-27
MY168937A (en) 2019-01-10
ZA201500856B (en) 2016-08-31
SG11201501392TA (en) 2015-05-28
MX2015004898A (es) 2015-07-21

Similar Documents

Publication Publication Date Title
JP5989250B2 (ja) Ｍｇｌｕｒ５受容体活性のモジュレーターとしてのエチニル誘導体
JP5753626B2 (ja) ピラゾリジン−３−オン誘導体
JP5989253B2 (ja) ｍＧｌｕＲ５受容体活性のモジュレータとしてのエチニル誘導体
JP6263542B2 (ja) Ｍｇｌｕｒ５受容体活性のモジュレーターとしてのエチニル誘導体
HK1207639B (en) Ethynyl derivatives as modulators of mglur5 receptor activity
HK1206715B (en) Ethynyl derivatives as modulators of mglur5 receptor activity
HK1208032B (en) Ethynyl derivatives as modulators of mglur5 receptor activity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160405

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160610

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160802

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160809

R150 Certificate of patent or registration of utility model

Ref document number: 5989250

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees